Why did Omega Diagnostics (ODX) share price surge last week?

The Omega Diagnostics (ODX) share price jumped over 20% last week. Zaven Boyrazian investigates what’s causing this sudden growth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Like many biotech companies that joined the fight against Covid-19 last year, the Omega Diagnostics (LSE:ODX) share price has seen some explosive growth. In 2020 alone, the stock surged more than 300%!

But by comparison, its recent performance has been quite disappointing. Since around March this year, the ODX share price has been on a downward trajectory, falling from around 100p to nearly 60p. However, towards the end of last week, the stock suddenly exploded by over 20%, rising to around 73p today. As a result, the 12-month performance now sits at around a 25% return. But what caused this growth?

ODX Share price: more growth on the horizon?

Omega Diagnostics is a small biotech firm. It primarily focuses on developing diagnostic products to detect food intolerances, allergies, and, more recently, viral infections like Covid-19. Its rapid progress in creating lateral flow antigen tests for the virus opened up several growth opportunities. In fact, this appears to be the primary driver behind the explosive ODX share price last year. But why is the stock price now surging again?

Recently, the management team made a series of promising announcements. 

The first relates to its government manufacturing contract. As a reminder, this agreement is for the production of rapid Covid-19 tests within the UK. Omega says it’s standing by, ready to start manufacturing tests just as soon as the Department of Health and Social Care (DHSC) gives the green light. Unfortunately, this process is taking longer than expected. However, it is worth noting that Omega Diagnostics has already received £2.5m (before VAT) in pre-production payments from the UK Government, and stands to benefit a great deal more once the ball gets rolling.

Secondly, the company has begun pursuing a CE mark for its antigen tests to enable it to start selling in Europe. Omega has actually already received a CE mark for professional use. But it wants to expand this to home use as well. As it stands, the management team expects approval by the end of July.

Combining these announcements, it seems that Omega Diagnostics is about to see a boom in both production and sales of its rapid Covid-19 tests. Needless to say, this offers some substantial growth for the business. And so, seeing the ODX share price take off is not that surprising to me.

The Omega Diagnostics ODX share price has its risks

There remain several risks

The potential growth that lies ahead is substantial in my eyes. However, whether this can be sustained over the long term remains to be seen. As it stands, Omega expects to generate a significant portion of its near-term future revenue from the sale of its Covid-19 tests. But as the vaccine rollout continues to progress worldwide, the demand for these products will likely decline, as may the ODX share price.

The company does have a diverse portfolio of alternative diagnostic products already on the market. But the income generated by these is not on the same scale as its most recent viral tests.

But the surge in initial income from the government manufacturing contract has flooded the balance sheet with plenty of cash. And this provides the management team with a notable amount of liquidity to pursue the development of new products to replace the Covid-19 sales in the future. But until such products are announced, Omega Diagnostics remains on my watch list.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Omega Diagnostics. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »